EMEA-002826-PIP01-20-M03
Table of contents
Key facts
| Invented name |
Veklury
|
| Active substance |
remdesivir
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0221/2022
|
| PIP number |
EMEA-002826-PIP01-20-M03
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Gilead Sciences International Ltd
E-mail: regulatory.pip@gilead.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|